Russell Greig, previously president of SR One, the corporate venturing arm of UK-listed pharmaceutical firm GlaxoSmithKline (GSK), has joined Israel-based phage therapy developer BiomX.
Greig had spent about 30 years at GSK and was at one time president of its Pharmaceuticals International subsidiary, and was president of SR One between 2008 and 2010.
During his time at the unit, Greig served as chairman of biopharmaceutical companies Ablynx and Syntaxin – both SR One portfolio companies the corporate later exited, through acquisitions by pharmaceutical firms Sanofi and Ipsen respectively.
Greig will chair the board of directors at BiomX, whose $32m series B round in early 2019 included corporates Johnson & Johnson and Takeda. He will contribute his pharmaceutical business development know-how, leveraging drug research and development experience.
Greig said in a statement: “Phage has the potential to become a disruptive therapeutic modality for the treatment of chronic diseases.
“BiomX, through a blend of state-of-the-art phage, computational biology and synthetic biology capabilities, is, we believe, at the forefront of this field. I look forward to working closely with the BiomX management team to advance the company’s programs.”
